Vanda Pharmaceuticals Shares Jump 17% After FDA Approved Fanapt for Bipolar I Disorder
By Sabela Ojea
Shares of Vanda Pharmaceuticals jumped 17% to $4.58 in post-market trading after the company said the Food and Drug Administration approved Fanapt to treat manic or mixed episodes associated with bipolar I disorder in adults.
The biopharmaceutical company said Tuesday the latest marketing approval increases the commercial opportunity of the treatment.
Fanapt has been used for the acute treatment of patients with schizophrenia since its FDA approval in 2009.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
April 02, 2024 18:59 ET (22:59 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software